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Abstract
BACKGROUND
According to the U.S. Center for Disease Control and Prevention, Clostridium difficile was responsible for 453
000 infections and approximately 29 000 deaths in the United States in 2011 alone. Newer, more virulent,
antibiotic-resistant strains of C. difficile are increasing rates of relapse making the disease is more difficult to
control than ever before. Efficacy of fecal microbiota transplant (FMT) for recurrent, refractory C. difficile
infection (CDI) has been proven in case studies and reports, but the first RCTs using this treatment option
have been published and will be analyzed in this systematic review.
METHODS
An exhaustive medical literature search was conducted using MEDLINE-Ovid, CINAHL, and Web of Science
using the following keywords and searches: 1) fecal microbiota transplant and clostridium difficile and 2)
clostridium difficile and feces and donor. The National Institute of Health clinical trials database was searched
using the terms “fecal microbiota transplant,” “clostridium difficile and feces,” and “donor feces” for completed
and published RCTs. Relevant articles for inclusion were assessed for quality using GRADE.
RESULTS
The search resulted in a total of 54 studies of which only two studies met inclusion criteria. The results from
both the van Nood et al study and the Youngster et al study demonstrate the positive outcomes of treating
recurrent, refractory CDI with fecal microbiota transplant (FMT). The van Nood et al study showed an
overall cure in 15 of 16 patients (94%) with donor feces infusion compared to cure in 4 of 13 patients (31%)
treated with vancomycin alone. According to the Youngster et al study, nasogastric tube (NGT) proves to be
the safer, patient-preferred route of FMT administration and is comparably effective when compared to
colonoscopy.
CONCLUSION
Based on the study results, FMT should be considered by clinicians as a safe and effective treatment option for
certain patients with recurrent, refractory CDI. It also appears viable to spare patients risks of colonoscopy by
administering the donor feces by upper GI route using NGT.
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ABSTRACT    
 
BACKGROUND   
According to the U.S. Center for Disease Control and Prevention, Clostridium difficile was 
responsible for 453 000 infections and approximately 29 000 deaths in the United States in 
2011 alone. Newer, more virulent, antibiotic-resistant strains of C. difficile are increasing 
rates of relapse making the disease is more difficult to control than ever before. Efficacy of 
fecal microbiota transplant (FMT) for recurrent, refractory C. difficile infection (CDI) has 
been proven in case studies and reports, but the first RCTs using this treatment option have 
been published and will be analyzed in this systematic review. 
 
METHODS 
An exhaustive medical literature search was conducted using MEDLINE-Ovid, CINAHL, and 
Web of Science using the following keywords and searches: 1) fecal microbiota transplant 
and clostridium difficile and 2) clostridium difficile and feces and donor. The National 
Institute of Health clinical trials database was searched using the terms “fecal microbiota 
transplant,” “clostridium difficile and feces,” and “donor feces” for completed and 
published RCTs. Relevant articles for inclusion were assessed for quality using GRADE. 
 
RESULTS 
The search resulted in a total of 54 studies of which only two studies met inclusion criteria. 
The results from both the van Nood et al study and the Youngster et al study demonstrate 
the positive outcomes of treating recurrent, refractory CDI with fecal microbiota transplant 
(FMT). The van Nood et al study showed an overall cure in 15 of 16 patients (94%) with 
donor feces infusion compared to cure in 4 of 13 patients (31%) treated with vancomycin 
alone. According to the Youngster et al study, nasogastric tube (NGT) proves to be the safer, 
patient-preferred route of FMT administration and is comparably effective when compared 
to colonoscopy. 
 
CONCLUSION 
Based on the study results, FMT should be considered by clinicians as a safe and effective 
treatment option for certain patients with recurrent, refractory CDI. It also appears viable to 
spare patients risks of colonoscopy by administering the donor feces by upper GI route 
using NGT. 
 
KEYWORDS   
Fecal Microbiota Transplant (FMT), donor feces transplant, Clostridium difficile, C. diff, 
infection, diarrhea, humans, vancomycin, antibiotics, colonoscopy, NGT 
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Fecal Microbiota Transplant (FMT) for the Treatment Of Recurrent, 
Refractory Clostridium difficile Infection: 
Comparison of FMT administration routes and cure of C. difficile 
colitis using FMT versus standard antibiotic therapy 
BACKGROUND 
 
Clostridium difficile—a gram-positive, spore-forming bacillus most prevalent in 
hospitals and chronic-care facilities1—is responsible for increased rates of morbidity and 
mortality in patients nationwide1,2 and is an increased burden to healthcare providers due 
to the high rate of recurrence.3 According to the U.S. Center for Disease Control and 
Prevention, C. difficile was responsible for 453 000 infections and approximately 29 000 
deaths in the United States in 2011 alone.2,4 In the last 15 years, the incidence of infections 
due to C. difficile has tripled.1,3 In some parts of the United States, it has even been 
suggested by data from 2011 that C. difficile infections are the most common etiology of 
healthcare-associated infections (HAIs)—even more than the infamous methicillin-resistant 
Staphylococcus aureus infections.5 Though the U.S. Department of Health and Human 
Services set a goal to reduce facility-onset C. difficile infections and hospitalizations with C. 
difficile by 30% individually, data revealed only a 2% reduction in facility-onset CDI and a 
17% increase in hospitalizations from baseline.6,7  
Not only do clinicians need to consider the increasing incidence of CDI, but also the 
increasing severity of the disease. A new strain of Clostridium difficile was discovered in the 
1980s8 and has been followed more closely since CDI epidemics in the U.S. and Canada from 
2000 to 2003 were linked with the strain.2 This new strain—referred to as restriction 
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enzyme analysis Type BI, North American PFGE type 1 or PCR-ribotype 027 (NAP1/027)2,8,9—
is not only a hyperproducer of toxins, but is also resistant to fluoroquinolone 
antimicrobials.2,9 It has been shown to be responsible for lower cure rates of CDI and 
increased recurrence rates when compared to other C. difficile strains.8 Their development 
is likely linked in part to increased antibiotic use—especially in healthcare settings, where 
the majority (at least 80%) of cases are contracted.1,2  
 Clinicians are constantly being reminded of the issues concerning antibiotic-
resistance and our contributing role by overprescribing antibiotics. The CDC reports that 
half of all hospitalized patients get antibiotics at some point during their stay despite 
studies showing that 30-50% of antibiotics prescribed in hospitals are unnecessary or 
incorrect.2 One study revealed that 85% of patients with C. difficile infection received 
antibiotics within 30 days of symptom onset.10 By prescribing broad-spectrum antibiotics for 
most bacterial infections, both pathologic and non-pathologic microbiota are killed, thus 
disrupting the balance of the sensitive human fecal microbiome.11 This dysbiosis facilitates 
infection by C. difficile either by overgrowth of indigenous spores (normally held to low 
quantities by native gut flora) or nosocomial acquisition of C. difficile.12 Current treatment 
of CDI using the standard antibiotics results in perpetuation of microbiome disturbance and 
put the patient at risk for recurrent or relapsing infection.1,3  
 With the newer, antibiotic-resistant NAP1/027 strain of C. difficile becoming more 
prevalent, the incidence of recurrent or relapsing CDI should be of great concern to 
clinicians. The rate of recurrence or relapse varies in the research, but clinicians should 
expect 15-35% of patients to have a second episode of CDI after treatment of the first 
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episode with appropriate antibiotic regimen—with most reinfections occurring within 8 
weeks of initial infection.1,13 Rates of failure after antibacterial therapy were comparable 
between the two antibiotics used for CDI treatment over the last 25 years—vancomycin and 
metronidazole.3,14  
  Clostridium difficile infection is increasing in prevalence, severity, and rates of 
recurrence or relapse despite—and often in correspondence to—antibiotic therapy. Thus, 
investigators are finally beginning to think outside the box for improved treatment of CDI. 
Administration of fecal enema was initially used in 1958 as a therapeutic method in the 
treatment of “fulminant, life-threatening pseudomembranous enterocolitis.”15 As we learn 
more about the importance of maintaining a balanced gut microbiome, there has been 
growing interest in restoring the microbiota through instillation of healthy, donor feces.16 
Right now, the concentration on microbiota restoration is targeted at patients with 
refractory CDI because of the presumed link between continued antibiotic treatments and 
increased displacement of normal gut flora in these individuals. A systematic review of 317 
patients across 27 case series and reports revealed disease resolution in 92% of cases after 
intestinal microbiota transplantation (IMT)—89% were cured after a single IMT treatment.17 
Though many case studies have shown positive treatment outcomes with use of fecal 
bacteriotherapy, randomized controlled trials (RTCs) have been lacking on the subject. This 
systematic review aims to answer questions using data from recent RCTs as to the 
superiority, safety, and feasibility of treating refractory CDI with fecal microbiota transplant 
versus standard antibiotic therapy, in addition to the most successful route of 
administration.  
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METHODS 
 
Literature Search 
An exhaustive medical literature search was conducted using the databases 
MEDLINE-Ovid, CINAHL, and Web of Science using the following keywords and searches:    
1) fecal microbiota transplant and clostridium difficile and 2) clostridium difficile and feces 
and donor. The search was then limited to include human-only studies in the English 
language. Abstracts were reviewed in search of randomized controlled trials with a 
comparison of interest. The National Institute of Health clinical trials database was also 
searched using the terms “fecal microbiota transplant,” “clostridium difficile and feces,” and 
“donor feces” for completed and published RCTs.19 Bibliographies of meta-analysis articles 
reviewing FMT treatment for C. difficile were also searched for any inclusions of RCTs.  
Eligibility Criteria 
 Articles included in this analysis were those designed as a randomized controlled 
trial comparing two different interventions regarding FMT as treatment for C. difficile with 
the primary outcomes being cure of C. difficile infection and prevention of relapse. The 
population of interest included patients of any age who experienced relapsing C. difficile 
colitis. Most patients in the studies had C. difficile infection refractory to a standard regimen 
of antibiotics, but this was not a requirement for analysis. Due to the low number of RCTs 
completed and published on this subject, no RCTs found were excluded from this systematic 
review. 
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Study Validity 
 Selected studies were analyzed for validity and risk of bias in addition to the overall 
quality assessment using Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).20 Selection bias was addressed by looking at randomization and 
concealing of study groups. Performance bias and detection bias were assessed through 
study blinding procedures. Attrition bias was addressed by whether or not the studies 
discussed and accounted for any missing outcome data. Lastly, reporting bias was assessed 
by reviewing articles for any significant, yet unreported, differences between the groups. 
RESULTS 
 
Search Results 
 The first keyword search on MEDLINE-Ovid resulted in 16 studies. The second 
keyword search on MEDLINE-Ovid resulted in 38 studies. After applying limitations and 
eligibility criteria, two randomized controlled trials21,22 were included in this systematic 
review. (See Table I.) 
The van Nood et al Study 
This randomized, controlled trial21 compared infusion of donor feces (FMT) to 
standard antibiotic regimen in the treatment of recurrent, refractory Clostridium difficile 
infection. The study had three treatment groups: 1) donor feces infusion, preceded by a 4-
day vancomycin regimen with bowel lavage, 2) 14-day vancomycin regimen, 3) 14-day 
vancomycin regimen with bowel lavage. This study took place in Amsterdam, The 
Netherlands, at the Academic Medical Center between January 2008 and August 2010. The 
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study planned to enroll a total of 120 patients—40 in each treatment arm. Patients were 
enrolled internally and also admitted from other hospitals based on physician referral with a 
visit by a study physician to confirm eligibility.21  
Of the 102 patients initially screened, only 43 participants were included in the study 
based on eligibility criteria. Inclusion criteria was outlined as being at least 18-years-old with 
a life expectancy of at least 3 months and history of relapsing CDI despite at least one 
course of standard antibiotic therapy (i.e., vancomycin 125 mg four times daily for at least 
10 days or metronidazole 500 mg three times daily for at least 10 days.) C. difficile infection 
was defined as 3 or more loose or watery stools per day for at least 2 days, or 8 or more 
loose stools in 48 hours, as well as a positive C. difficile toxin in stool. Criteria for exclusion 
included compromised immunity (i.e., recent chemotherapy, HIV infected with CD4 count 
less than 240, chronic use of prednisone in quantities greater than or equal to 60 mg per 
day); antibiotic use other than for CDI; current pregnancy; requirement of vasopressors; or 
admission to an ICU.21  
Randomization was achieved by using an automated biased coin minimization. There 
was neither blinding nor concealment of allocation per the study design. Patients were 
initially stratified on whether they would be inpatient or outpatient and by the number of 
recurrent infections at the start of the trial. Of the 43 total subjects at the time of 
randomization, 17 were assigned to receive the donor feces infusion, 13 were assigned to 
receive vancomycin only, and 13 were assigned to receive vancomycin plus bowel lavage.21  
Patients in the first treatment group received 4 days of vancomycin (500 mg four 
times daily), followed by bowel lavage using macrogol solution on the last day of 
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vancomycin treatment. The following day, they received an infusion through nasogastric 
tube (NGT) administration with a mean of 141+/-71 g of fresh donor feces. Exact methods 
for monitoring safety, quality, and preparation of donor feces infusion was outlined in the 
article but will not be discussed in this review.21 Patients in this treatment group were given 
a second donor feces infusion if they developed a recurrent C. difficile infection. Patients in 
the second treatment group received vancomycin 500 mg four times daily for 14 days. 
Patients in the third treatment group received the same vancomycin regimen as the second 
group, but also received a bowel lavage with macrogol solution on day 4 or 5 of the 
regimen. Patients with continued C. difficile in the antibiotic control groups were offered 
donor feces infusion off protocol. Results were compiled using stool diaries kept by the 
patients and study follow up was concluded 10 weeks after administration of treatment.21    
The primary outcome of the study was cure of CDI without relapse within 10 weeks 
of treatment administration. Secondary outcome was cure of CDI without relapse after 5 
weeks. Cure was defined as absence of diarrhea and three consecutive negative stool tests 
for C. difficile toxin. Relapse was defined as presence of diarrhea with positive stool test for 
C. difficile toxin. The study was terminated early by the data and safety monitoring board 
due to the unexpected low rates of cure and increased relapse in both vancomycin groups. 
Of 43 participants initially randomized into study arms, 41 patients completed the study 
protocol—one lost from the infusion group and one from the vancomycin-only group.21  
Cure of CDI without relapse occurred in 13 (81%) of the 16 patients in the donor 
feces group after the first treatment. After a subsequent treatment with a different donor 
feces sample, another 2 patients were cured, which gave an overall resolution of infection 
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in 15 of 16 patients (94%) in the group receiving the donor feces infusion. Cure in the 
vancomycin-only group occurred in 4 of 13 patients (31%, P<0.001) with relapse in 8 of 13 
patients (62%). In the group receiving vancomycin plus bowel lavage, 3 of 13 patients (23%, 
P<0.001) were cured with relapse in 7 of 13 (54%). The main adverse events that occurred 
in the donor-feces infusion group included diarrhea (94%), cramping (31%) and belching 
(19%)—all of which subsided within 3 hours of administration. Three patients in this group 
(19%) reported constipation during follow up.21  
The diversity of fecal microbiota of the participants receiving donor feces infusion 
was assessed before and after treatment using The Simpson’s Reciprocal Index of diversity. 
Prior to infusion, the diversity was low across this study arm, but it increased a three-fold 
average to the same level of diversity as the donors within 2 weeks of infusion.  It was also 
shown that this increased level of diversity remained consistent through follow up. Overall, 
the authors of this randomized, controlled trial conclude that infusion of donor feces has a 
superior treatment outcome when compared to vancomycin in patients with recurrent, 
refractory C. difficile infection—likely due to improvement in microbial diversity.21 
The Youngster et al Study 
 
This randomized, controlled trial22 adds important, supported protocol for preferred 
administration and cure of relapsing Clostridium difficile infection using FMT. The study was 
conducted at Massachusetts General Hospital between the dates of December 2012 and 
May 2013. Primary outcome of interest was resolution of diarrhea (<3 bowel movements 
per 24 hours) and cure of CDI while off antibiotics, without relapse for 8 weeks after 
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treatment. Secondary endpoints included subjective improvement in well-being by the 
participants and any adverse events that occurred with treatment.22 
After assessing 37 patients for study eligibility, a total of 20 patients were included in 
the study. Participants between the ages of 7 and 90 were included if they had relapsing (at 
least 3 episodes of CDI with vancomycin and/or other alternative antibiotic taper) or 
refractory (at least 2 episode of CDI resulting in hospitalization and significant morbidity) C. 
difficile infection. Patients were excluded if there was an anatomic contraindication to NGT 
or colonoscopy procedure; recurrent aspirations or delayed gastric emptying syndrome; 
immunosuppression (defined fully in article); pregnancy; more than 40 mg of oral 
prednisone daily; history of significant allergies to food.22 
Patients were assigned to treatment arms based on a computer-generated 
randomization in blocks of 4. There was no blinding or allocation concealment per study 
design. All participants discontinued any antibiotics at least 48 hours prior to treatment 
administration. Donor feces was prepared fresh and suspended with saline and 10% 
glycerol prior to being frozen for use as study inoculum.  Complete specifics of screening, 
obtaining, and preparing donor fecal inoculum were detailed in the article and will not be 
reviewed here.22 
The first treatment arm received FMT via NGT. They were given up to 20 mg of 
omeprazole 48 hours before the procedure and were given a total of 90 cc of the fecal 
inoculum for the procedure itself. The second treatment arm received FMT via endoscopic 
insertion into the right colon. This group underwent bowel preparation with polyethylene 
glycol prior to the procedure. A total of 90 cc of fecal inoculum was diluted to 160 cc for 
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pediatric patients and 250 cc for adults. Participants were instructed to retain the inoculum 
for as long as possible and were given one dose of loperamide to facilitate this instruction. 
Patients in both groups who showed no improvement after the first treatment were offered 
a second treatment by their preferred route of administration.22  
Patients were followed for a total of 6 months after treatment administration with 
questionnaires reporting their stool frequency and consistency, their overall well-being, and 
any adverse events. After the first donor feces treatment, 14 of the 20 participants were 
cured: 6 in the NGT group and 8 in the colonoscopy group. Of the 6 patients who continued 
to have symptoms after the first treatment, 5 chose to get a second treatment with the 
route of their choosing. All 5 chose to get their second treatment via NGT and 4 of the 5 
were subsequently cured. This resulted in an overall 90% cure rate (80% in the NGT group 
and 100% in the initial colonoscopy group) without relapse after receiving FMT 
administration with donor feces for recurrent or refractory CDI.22  
Secondary outcomes measuring subjective improvement in well-being was assessed 
with a standardized questionnaire with ratings from 1-10, with 10 being “your best recent 
health baseline.” Patients in the NGT group had a median score of 4 prior to FMT 
administration, which increased to a score of 7 at the 8-week follow up point. Similarly, the 
colonoscopy group had a median score of 5 prior to FMT administration, which increased to 
a score of 8 at the 8-week follow up point.22  
Adverse events related to treatment administration included mild abdominal 
discomfort and bloating in 4 patients (20%), but there was no delineation as to the 
treatment route that these patients were assigned. They did report that one child in the 
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colonoscopy group had a fever of 38.8 degrees on day 2 after treatment, but it was 
transient and resolved spontaneously. Other adverse events occurred but were not 
associated with donor feces transplant. These included 2 deaths from unrelated health 
conditions, 1 cancer diagnosis and 1 hospitalization for Fournier gangrene.22 
Lastly, fecal microbiota from recipients was compared to that of donors at 44 
different time points after FMT administration. Though the recipients had consistently low 
microbiota diversity at the prior to treatment, the diversity after FMT increased to a level 
comparable to that of the donor feces. As it showed in the trial’s chosen Shannon diversity 
index, the route of administration (NGT vs. colonoscopy) to increase native microbiota 
resulted in a negligible difference. Overall, the authors of this randomized, controlled trial22 
conclude that the efficacy of FMT by route of NGT to treat recurrent CDI is comparable to 
colonoscopic infusion but with less associated risks.22  
DISCUSSION   
 Fecal Microbiota Transplant using donor feces has been proven effective in 
producing cure of refractory CDI across several case studies and case reports.17 However, 
the existing variability in these published results with regard to patient and donor 
populations, protocol for donor feces inoculum preparation, and route of administration 
leave many questions for clinicians and researchers. This is why the two recently published 
RCTs discussed in this review are an important step in researching the novel, functional 
approach to Clostridium difficile infection management that FMT provides. 
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Outcomes 
 
 The results from both the van Nood et al study21 and the Youngster et al study22 
demonstrate the positive outcomes of treating recurrent, refractory CDI with FMT. The van 
Nood et al study21 showed cure of recurrent CDI in 13 of 16 patients (81%) after initial 
donor feces infusion and an overall cure in 15 of 16 patients (94%) after re-treatment with 
FMT for refractory CDI. This was a much more favorable response rate when compared to 
both vancomycin alone (cure in 4 of 13 patients—31%) and vancomycin plus bowel lavage 
(cure in 3 of 13 patients—23%).  The relative risk (RR) of treatment with FMT versus 
vancomycin alone was approximately 3, which means that there was a three-fold increase 
in rate of cure without relapse at 10 weeks post-treatment with FMT compared to 
vancomycin. Similarly, the Youngster et al study22 showed cure in 14 of 20 patients (70%) 
after initial FMT—using either NGT or colonoscopy—and cure in 18 of 20 patients (90%) 
after second infusion. In fact, the success of FMT compared to both control arms in the van 
Nood et al study21 led to early termination and closed enrollment after only 43 of the 
planned 120 patients completed the study.  Though these two RCTs21,22 had small sample 
sizes, the results provide depth and consistency to the meta-analysis of case studies and 
reports demonstrating resolution of recurrent CDI in 92% of cases.17  
 Not only was the overall efficacy of FMT studied, but also the important comparison 
of effective and preferred route of administration of FMT—NGT or colonoscopy.22 It was 
demonstrated that both routes were comparably effective, especially when taking into 
consideration that one patient in the NGT group refused to undergo subsequent treatment 
after initial FMT treatment failure. It is of interest that the other 5 patients without cure 
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after first FMT administration in the Youngster et al study22 chose (per study protocol) to 
receive their second treatment via NGT administration. Additionally, no complications of 
vomiting or aspiration occurred with this upper GI route. Therefore, NGT proves to be the 
safer, comparably effective, and preferred route of FMT administration when compared to 
colonoscopy. This finding will save patients from unnecessary sedation and undesirable 
bowel prep.22 
Secondary outcomes observed include increased subjective well-being by the 
participants in both FMT treatment arms of the Youngster et al study22 and common, yet 
mild and transient, adverse gastrointestinal events in both studies.21,22 These adverse events 
reported do not outweigh the benefits of considering donor feces infusion for patients with 
recurrent or refractory CDI who fit the eligibility criteria of these RCT study participants.21,22 
Though bacterial diversity was not an explicit outcome of interest in either study, both 
studies did include this assessment in their study design and research results. Using a 
diversity index calculator, both studies showed that study recipients of donor feces had 
decreased fecal bacterial diversity prior to FMT and had markedly increased levels 
comparable to donors immediately after FMT. Of great importance is that these levels had 
sustained elevation even two weeks after treatment. This finding adds additional evidence 
to the physiologic basis supporting FMT that assumes the donor bacteria occupies niches in 
the gut, which leads to restoration of the structure and function of the gut microbiome as a 
host defense.21,22,23   
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Limitations 
 
Though the resultant evidence from these two trials21,22 is promising, it is not 
without both clinical and logistical flaws. The first thing that the clinician needs to consider 
when assessing FMT for clinical use is the fact that these two RCTs had a narrow study 
population that excluded groups most likely to have severe CDI: immunodeficient patients, 
ICU patients, and patients requiring concurrent antibiotics for reasons other than CDI.21,22 
The greatest incidence of CDI occurs in patients 65 years of age or older,2,4 but other known 
risk factors include severity of comorbidities, previous gastrointestinal surgery, antacid 
treatment, use of electronic rectal thermometers, and enteral tube feeding—all extremely 
prevalent characteristics across patient populations.1 Taking into consideration the excluded 
populations, in addition to patients with any of the above risk factors, the risk-benefit 
assessment could be much different. Therefore, adapting FMT as a treatment option given 
the current research must be at the discretion of individual providers. 
Another factor to consider is that patients included in the van Nood et al study21 had 
an average of 2-3 relapses of CDI with prior antibiotic treatment at study initiation. 
Therefore, it is plausible to assume that the CDI in the van Nood et al study 21 may be 
resistant to repeated vancomycin therapy, which led to decreased treatment effects. This 
demonstrated lack of cure with repeated antibiotic therapy should make clinicians more 
willing to consider treatment with FMT after a second or third relapse of refractory CDI.21 
A GRADE quality assessment was performed in this systematic review to analyze 
limitations and applicability of the studies.20 (See Table I.) The major limitations that led to 
quality downgrades were no blinding or allocation concealment in either study, as well as 
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small sample sizes. There was also no control group in the Youngster et al study.22 Study 
limitations downgraded these RCTs to Low. However, the studies were then upgraded in 
quality by one level based on large RR values for the following outcomes: 1) Cure of CDI 
without relapse within 8-10 weeks of initial therapy and 2) Relapse within 5 weeks of initial 
therapy. Improvement in subjective well-being, as studied by Youngster et al,22 did show 
improvement across study arms and is a patient-important outcome to consider. Adverse GI 
symptoms (though mild and short-lived) were common in both studies, but sample size 
limited the quality of evidence of this outcome. In the end, the GRADE assessment for the 
critical outcomes of interest in this systematic review resulted in overall Moderate quality.  
Further Research 
 
 This area of research is already quickly emerging and several additional trials are 
underway to further validate and standardize FMT as a treatment for C. difficile infection.19 
It will be important that this research include RCTs with better study design quality—
including larger sample sizes, set control groups, and proper blinding and allocation 
concealment. There should be emphasis placed on protocol for donor feces inoculum 
preparation, as well as cost-effective and efficient solutions for procuring donor feces. The 
overall costs associated with mainstream FMT should be included in further research, but 
studies must compare it to the current costs of CDI management (estimated at an annual 
$3.2 billion dollars nationally as reported in 2005 US dollars).24 For FMT to be a viable 
treatment option adopted in clinics it need not only be proven safe and effective, but also 
easily accessible and aesthetically tolerable to patients. 
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CONCLUSION  
 Fecal microbiota transplant proves to be a groundbreaking treatment option for the 
growing problems associated with recurrent or relapsing C. difficile infection refractory to 
initial antibiotic therapy. It improves patient-important outcomes including cure of CDI 
without relapse at 8-10 weeks after treatment, subjective improvement in well-being, and 
increased fecal bacterial diversity. These results were obtained with an acceptable level of 
adverse events due to FMT. Furthermore, it appears that NGT offers an accessible, 
effective, and patient-preferred route of administration at this time. These practices are 
both safe and effective for certain patient populations that must be assessed individually by 
clinicians.  
These findings are of vital significance in the current climate of newer, more virulent, 
antibiotic-resistant strains of C. difficile that are at the forefront of the disease progression. 
Though RCTs are just starting to emerge on the subject, there is enough quality evidence 
published that CDI treatment guidelines14,24 are suggesting that clinicians consider FMT for 
patients with recurrent CDI based on the likelihood that the native gut microbiome is 
disrupted. Clinicians must also accept their role in Clostridium difficle disease prevention by 
implementing better practices of prescribing antibiotics. This should include restriction of 
unnecessary antibiotic prescriptions, decreased frequency and duration of prescriptions, 
and more targeted antimicrobials to local epidemiology. Though fecal therapy for similar 
colonic diseases is over 50 years old, new light on the use of FMT will likely facilitate 
improved CDI management by clinicians for decreased disease morbidity and mortality.  
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TABLE I. GRADE QUALITY ASSESSMENT OF STUDIES 
 
 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
 
a No blinding in either study21,22  
b No allocation concealment in either study21,22 due to trial procedures 
c No control group by design in Youngster et al study22 
d The van Nood et al study21 was stopped early because of large magnitude of treatment effects noted. 
e There were small sample sizes in both studies,21,22 however there were large magnitude of treatment effects noted which maintained precision. The 
adverse events were a secondary outcome and require larger trials. 
f Upgraded one level due to RR > 2 
 
QUALITY ASSESSMENT 
 Downgrade Criteria  
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study/Studies Quality Importance 
Cure of CDI without relapse within 8-10 weeks of initial therapy 
2 RCT Very serious limitationsa,b,c 
No serious 
indirectness 
No serious 
imprecisiond,e 
No serious 
inconsistencies 
No bias 
likely 
van Nood et al21 
Moderatee,f Critical 
Youngster et al22 
Relapse within 5 weeks of initial therapy  
1 RCT  Very serious limitationsa,b 
No serious 
indirectness 
No serious 
imprecisiond,e 
No serious 
inconsistencies 
No bias 
likely van Nood et al
21 Moderatee,f Critical 
Presence of adverse events 
2 RCT Very serious limitationsa,b,c 
No serious 
indirectness 
Serious 
imprecisiond,e 
No serious 
inconsistencies 
No bias 
likely 
van Nood et al21 
Very low Important 
Youngster et al22 
Improvement in subjective well-being  
1 RCT Very serious limitationsc 
No serious 
indirectness 
No serious 
imprecisione 
No serious 
inconsistencies 
No bias 
likely Youngster et al
22 Low Important 
